title: [A novel immunoregulating hexapeptide with antineoplastic effect].
abstract: A synthesized analog of myelopeptide HP-2-->M[symbol: see text]-2 (Leu-Val-Val-Tyr-Pro-Trp) caused a significant (60-80%) and prolonged inhibition of s.c. grafted tumors P388, Ca-755, B-16 and sarcoma 180 in isogenic mice but did not affect the growth of tumor B-16 in nude mice. Nor did it influence proliferative activity or viability of cultured human tumor cells. The best results were obtained with s.c. injections of 0.5-2 mg/kg HP-2-->M[symbol: see text]-2, twice or trice a day, at 96 hr intervals. No symptoms of severe poisoning were registered at doses of HP-2-->M[symbol: see text]-2 100 times the therapeutic one. A pharmacokinetic study in mice revealed prolonged circulation of HP-2-->M[symbol: see text]-2 in blood and a high affinity for the bone marrow (t 1/2 (130.1 hr and 431.6 hr, respectively). HP-2-->M[symbol: see text]-2 restored in vitro the ascites P388-suppressed cytotoxicity of murine T-lymphocytes. HP-2-->M[symbol: see text]-2 is regarded as a candidate for clinical studies of its potential of immunocorrection in cancer patients suffering T-lymphocyte immunity disturbances.
authors.affiliation: N.N. Blokhin Center for Oncology Research, Russian Academy of Medical Sciences, Moscow.
authors.forename: E M
authors.initials: EM
authors.lastname: Treshchalina
authors.forename: L A
authors.initials: LA
authors.lastname: Sedakova
authors.forename: N K
authors.initials: NK
authors.lastname: Vlasenkova
authors.forename: O S
authors.initials: OS
authors.lastname: Zhukova
authors.forename: G A
authors.initials: GA
authors.lastname: Firsova
authors.forename: L M
authors.initials: LM
authors.lastname: Mikhaĭlova
authors.forename: E Iu
authors.initials: EIu
authors.lastname: Kolesnikova
authors.forename: N I
authors.initials: NI
authors.lastname: Zimakova
authors.forename: S V
authors.initials: SV
authors.lastname: Khabarov
authors.forename: G K
authors.initials: GK
authors.lastname: Gerasimova
mesh_terms: D000276:Adjuvants, Immunologic / Q000493:pharmacokinetics / Q000494:pharmacology*; D000818:Animals; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology; D007941:Leukemia P388 / Q000188:drug therapy; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy; D008546:Melanoma, Experimental / Q000188:drug therapy; D051379:Mice; D008807:Mice, Inbred BALB C; D008811:Mice, Inbred DBA; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D009842:Oligopeptides / Q000493:pharmacokinetics / Q000494:pharmacology*; D012510:Sarcoma 180 / Q000188:drug therapy; D013601:T-Lymphocytes / Q000187:drug effects; D014407:Tumor Cells, Cultured
chemical_list: D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D007155:Immunologic Factors; D009842:Oligopeptides; C048617:myelopeptides